Olaf Stuve

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease
    Olaf Stuve
    Department of Neurology, University of California, San Francisco, CA 94143 0114, USA
    J Immunol 169:6720-32. 2002
  2. ncbi Knowns and unknowns in the future of multiple sclerosis treatment
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    J Neurol Sci 287:S30-6. 2009
  3. ncbi Factors that influence adherence with disease-modifying therapy in MS
    Katherine Treadaway
    Dept of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    J Neurol 256:568-76. 2009
  4. ncbi Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab
    Maria del Pilar Martin
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 65:1596-603. 2008
  5. ncbi The effects of natalizumab on the innate and adaptive immune system in the central nervous system
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    J Neurol Sci 274:39-41. 2008
  6. ncbi CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke
    Ann M Stowe
    Department of Neurological Surgery, Washington University School of Medicine, 660 S, Euclid Ave, Box 8057, St, Louis, MO 63110, USA
    J Neuroinflammation 9:33. 2012
  7. ncbi DNA-based vaccines: the future of multiple sclerosis therapy?
    Olaf Stuve
    VA North Texas Health Care System, Neurology Section, Medical Service, 4500 South Lancaster Road, Dallas, TX 75216, USA
    Expert Rev Neurother 8:351-60. 2008
  8. ncbi Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
    O Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    Neurology 72:396-401. 2009
  9. ncbi Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions
    Olaf Stuve
    Neurology Section, Medical Service, Veterans Affairs North Texas Health Care System, Dallas, TX, USA
    Arch Neurol 64:169-76. 2007
  10. ncbi Pharmacological treatment of early multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
    Drugs 68:73-83. 2008

Detail Information

Publications55

  1. ncbi The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease
    Olaf Stuve
    Department of Neurology, University of California, San Francisco, CA 94143 0114, USA
    J Immunol 169:6720-32. 2002
    ..These results do not support the role of astrocytes as APC for class II-restricted Ag presentation during the induction phase of EAE...
  2. ncbi Knowns and unknowns in the future of multiple sclerosis treatment
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    J Neurol Sci 287:S30-6. 2009
    ..Future therapeutic agents will also have to be designed to address the neurodegenerative component of the physiopathology of multiple sclerosis...
  3. ncbi Factors that influence adherence with disease-modifying therapy in MS
    Katherine Treadaway
    Dept of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    J Neurol 256:568-76. 2009
    ..The aim of this investigation was to identify which factors most influenced nonadherent behavior with the available disease-modifying injection therapies for multiple sclerosis (MS)...
  4. ncbi Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab
    Maria del Pilar Martin
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 65:1596-603. 2008
    ..We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS...
  5. ncbi The effects of natalizumab on the innate and adaptive immune system in the central nervous system
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    J Neurol Sci 274:39-41. 2008
    ..In addition, we demonstrated that the cell numbers in CSF remained unchanged even 6 months after cessation of natalizumab treatment...
  6. ncbi CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke
    Ann M Stowe
    Department of Neurological Surgery, Washington University School of Medicine, 660 S, Euclid Ave, Box 8057, St, Louis, MO 63110, USA
    J Neuroinflammation 9:33. 2012
    ..We hypothesized that such a hypoxia-induced upregulation of CCL2 is required for HPC-induced ischemic tolerance...
  7. ncbi DNA-based vaccines: the future of multiple sclerosis therapy?
    Olaf Stuve
    VA North Texas Health Care System, Neurology Section, Medical Service, 4500 South Lancaster Road, Dallas, TX 75216, USA
    Expert Rev Neurother 8:351-60. 2008
    ..This review will discuss these intriguing observations and the overall potential of DNA vaccination in MS...
  8. ncbi Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
    O Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA
    Neurology 72:396-401. 2009
    ....
  9. ncbi Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions
    Olaf Stuve
    Neurology Section, Medical Service, Veterans Affairs North Texas Health Care System, Dallas, TX, USA
    Arch Neurol 64:169-76. 2007
    ..Because it is currently impossible to identify patients at risk, and thus to prevent PML as a consequence of natalizumab therapy, it is important that neurologists be aware of possible therapeutic interventions...
  10. ncbi Pharmacological treatment of early multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
    Drugs 68:73-83. 2008
    ....
  11. ncbi alpha4-Integrin antagonism with natalizumab: effects and adverse effects
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, 4500 South Lancaster Rd, Dallas, TX 75216, USA
    J Neurol 255:58-65. 2008
    ..They also suggest that natalizumab treatment may result in prolonged immunosuppression in peripheral organs, and the delayed onset of adverse events...
  12. ncbi Immune surveillance in multiple sclerosis patients treated with natalizumab
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, USA
    Ann Neurol 59:743-7. 2006
    ....
  13. ncbi Translational research in neurology and neuroscience 2010: multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 67:1307-15. 2010
    ..This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients...
  14. ncbi Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
    Amer Awad
    PhD Departments of Neurology and Immunology, University of Texas Southwestern Medical Center at Dallas, TX, USA and Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA
    Ther Adv Neurol Disord 2:50-61. 2009
    ..Finally, an outlook into relatively novel treatment approaches is provided...
  15. ncbi Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
    Olaf Stuve
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, USA
    Arch Neurol 63:1383-7. 2006
    ....
  16. ncbi A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease
    Doris Lambracht-Washington
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, United States
    J Neuroimmunol 254:63-8. 2013
    ....
  17. ncbi Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease
    Bao Xi Qu
    Alzheimer s Disease Center, Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9036, USA
    Vaccine 28:5280-7. 2010
    ..These results demonstrate the potential therapeutic use of Gal4/UAS DNA A beta 42 trimer immunization in preventing Alzheimer's disease...
  18. ncbi Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein
    Christopher T Harp
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Eur J Immunol 40:2942-56. 2010
    ..Our results demonstrate for the first time that the memory B-cell pool in RRMS harbors neuro-Ag specific B cells that can activate T cells...
  19. ncbi Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis
    Olaf Stuve
    Division of Neurology, Medicine Service, Dallas Veterans Affairs Medical Center, Dallas, Texas, USA
    Arch Neurol 66:259-61. 2009
    ..The clinical and paraclinical efficacy of rituximab was demonstrated recently in a phase 2 clinical trial in patients with RRMS...
  20. ncbi Depletion of B lymphocytes from cerebral perivascular spaces by rituximab
    Maria del Pilar Martin
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Arch Neurol 66:1016-20. 2009
    ..We and other investigators previously demonstrated that rituximab therapy depletes B lymphocytes from peripheral blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis...
  21. ncbi Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
    Clemens Warnke
    Neurology Section, VA North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 67:923-30. 2010
    ..In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment...
  22. ncbi DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation
    Doris Lambracht-Washington
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9036, USA
    Cell Mol Neurobiol 31:867-74. 2011
    ..Therefore, Aβ42 DNA trimer immunization has a high probability to be effective and safe to treat patients with early AD...
  23. ncbi Objective characterization of the relative afferent pupillary defect in MS
    Paul Blazek
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, USA
    J Neurol Sci 323:193-200. 2012
    ..To develop an objective and precise neurophysiologic method from which to identify and characterize the presence and magnitude of relative afferent pupillary defects (RAPD) in patients with MS...
  24. ncbi Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet
    Petra D Cravens
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Neuroinflammation 8:73. 2011
    ..Our data further suggest that GM-CSF expression by CD4+ T cells regulated by IL-23 contributes to their encephalitogenicity in our EAE model...
  25. ncbi Direct and consensual murine pupillary reflex metrics: establishing normative values
    Rehana Z Hussain
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9036, USA
    Auton Neurosci 151:164-7. 2009
    ..Here, we have established normal reference values for various pupillary reflex metrics across different mouse strains. Ultimately, we anticipate that this new data will help to catalyze unique lines of inquiry using pupillometry methods...
  26. ncbi Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling
    Wei Hu
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA
    Brain 133:375-88. 2010
    ..Our data identify cellular prion protein as a regulator of cellular immunological homoeostasis and suggest cellular prion protein as a novel potential target for therapeutic immunomodulation...
  27. ncbi Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success
    Benjamin M Greenberg
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8806, USA
    Mult Scler 18:1022-6. 2012
    ..Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking...
  28. ncbi PEG minocycline-liposomes ameliorate CNS autoimmune disease
    Wei Hu
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
    PLoS ONE 4:e4151. 2009
    ..Here, we investigated whether less frequent treatment with long-circulating polyethylene glycol (PEG) minocycline liposomes are effective in treating EAE...
  29. ncbi Prion proteins: physiological functions and role in neurological disorders
    Wei Hu
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX 75390 9036, United States
    J Neurol Sci 264:1-8. 2008
    ..In this review, we summarize accumulating in vitro and in vivo evidence regarding the physiological functions of PrP(C) in the nervous system, as well as in lymphoid organs...
  30. ncbi Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects
    Anjali Shah
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Neurotherapeutics 4:627-32. 2007
    ..Nevertheless, we will focus on the rationale and practical schemes that can be considered for using corticosteroids (CS) (and perhaps even ACTH) in an attempt to modify various domains of ongoing disease activity...
  31. ncbi Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
    Amer Awad
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Neuroimmunol 219:1-7. 2010
    ..In this review we discuss the history of CSF diagnostic tests and the most recent methodological advances. We also outline the potentially important diagnostic role and possible limitations of these tests...
  32. ncbi DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model
    Doris Lambracht-Washington
    Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9108, USA
    JAMA 302:1796-802. 2009
    ....
  33. ncbi Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis
    Elliot M Frohman
    Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Arch Neurol 65:26-35. 2008
    ..Here we underscore the potential utility of the anterior visual system for the purpose of modeling neuroprotection in response to novel therapies...
  34. ncbi Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications
    Jeffrey L Bennett
    Department of Neurology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Neuropharmacol 32:121-32. 2009
    ..On the basis of these observations, new therapeutic approaches for MS will need to focus on resetting multiple components of the immune system...
  35. ncbi Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician
    Aaron Boster
    The Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine, and The Detroit Medical Center, Detroit, MI 48201, USA
    Lancet Neurol 7:173-83. 2008
    ..This Review describes the use of intense immunosuppressant drugs and natalizumab in patients with rapidly worsening MS and provides clinicians with guidelines for the use of these drugs in this patient group...
  36. ncbi Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations
    Elliot M Frohman
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Arch Neurol 62:1519-30. 2005
    ....
  37. ncbi Quinpramine is a novel compound effective in ameliorating brain autoimmune disease
    Mahendra P Singh
    Department of Neurology, University of Texas Southwestern, Dallas, USA
    Exp Neurol 215:397-400. 2009
    ..Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS...
  38. ncbi A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)
    Gina M Remington
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Ther Adv Neurol Disord 3:3-13. 2010
    ..Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted...
  39. ncbi Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease
    Anne R Gocke
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    J Immunol 182:4479-87. 2009
    ..Finally, therapeutic administration of PPARalpha agonists ameliorated clinically established EAE, suggesting that PPARalpha agonists may provide a treatment option for immune-mediated inflammatory diseases...
  40. ncbi Corticosteroids for multiple sclerosis: I. Application for treating exacerbations
    Elliot M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Neurotherapeutics 4:618-26. 2007
    ..This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients...
  41. ncbi Immunologic mechanisms of multiple sclerosis
    Elliot M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    Neuroimaging Clin N Am 18:577-88, ix. 2008
    ....
  42. ncbi Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis
    E M Frohman
    Departments of Neurology and Ophthalmology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    Arch Neurol 63:614-9. 2006
  43. ncbi Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions
    E M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA
    Arch Neurol 62:1345-56. 2005
    ....
  44. ncbi Therapeutic potential of small interfering RNA for central nervous system diseases
    Amy E Lovett-Racke
    Department of Neurology, UT Southwestern Medical Center, Dallas, Tex 75390-9036, USA
    Arch Neurol 62:1810-3. 2005
  45. ncbi A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
    Elliot M Frohman
    Departments of Neurology and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Ther Adv Neurol Disord 3:15-28. 2010
    ..Conclusions: The results from this pilot study suggest that the application of MMF monotherapy in MS deserves further exploration...
  46. ncbi No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis
    Ellen Marder
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas VA Medical Center, 4500 South Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 68:1521-5. 2011
    ..To determine if chronic cerebral venous insufficiency exists in patients with multiple sclerosis (MS) using ultrasonography and 4-dimensional color Doppler ultrasonography examination and unverified criteria proposed by Zamboni et al...
  47. ncbi Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis
    Nancy L Monson
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 6:e17103. 2011
    ..While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues...
  48. ncbi Optical coherence tomography in multiple sclerosis
    Elliot Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA
    Lancet Neurol 5:853-63. 2006
    ..In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis...
  49. ncbi Risks and benefits of multiple sclerosis therapies: need for continual assessment?
    Bernd C Kieseier
    Curr Opin Neurol 24:238-43. 2011
    ....
  50. ncbi Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas, USA
    CNS Drug Rev 13:79-95. 2007
    ..In addition, an overview of pharmacological properties, clinical efficacy, safety, and toxicology of natalizumab is provided...
  51. ncbi W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century
    Elliot M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75235, USA
    Arch Neurol 64:452-4. 2007
  52. ncbi Multiple sclerosis in the elderly patient
    Amer Awad
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Drugs Aging 27:283-94. 2010
    ..Given the overall aging of the population, focusing on these two patient groups appears highly relevant...
  53. ncbi Symptomatic therapy in multiple sclerosis
    Teresa C Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Ther Adv Neurol Disord 4:83-98. 2011
    ....
  54. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  55. ncbi Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis
    S L Davis
    Institute for Exercise and Environmental Medicine, Presbyterian Hospital of Dallas, TX, USA
    Neurology 70:1098-106. 2008
    ....